Helix BioPharma Closes Private Placement

Helix BioPharma (TSX:HBP) an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD940,800.

As quoted in the press release:

The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with the private placement.

Click here to read the full press release.